Citations

Mayo Clinic

Showing 10 of 108599 citations.

Sex Differences in Fluorouracil-Induced Stomatitis
Sloan, Jeff A. , Loprinzi, Charles L. , Novotny, Paul J. , Okuno, Scott H. , Nair, Suresh , Barton, Debra L.

Journal of Clinical Oncology | February 24, 2017 | Volume: 18 | Issue: 2 | Pages: 412-412

10.1200/jco.2000.18.2.412 | PMID 10637257 Get It

PURPOSE: A meta-analysis of six North Central Cancer Treatment Group (NCCTG) trials involving patients receiving their first ever fluorouracil (5-FU)–based chemotherapy was undertaken to explore the association of sex with reports of the incidence and severity of stomatitis. PATIENTS AND METHODS: Data were obtained on a total of 731 patients (402 men and 329 women). Comparisons of incidence and severity rates and average stomatitis across sex were performed using standard binomial testing and t tests, respectively. Logistic regression analysis and a weighted analysis using data summarized to study level served as evidence of cross-validation. RESULTS: Women reported stomatitis both more often and with greater severity than did men. The incidence of any stomatitis for women was 63% versus 52% for men (P = .002). The incidence of severe or very severe stomatitis for men and women was 22% and 12%, respectively (P = .0006). On average, women reported stomatitis of roughly 0.4 points higher than men on a 0 to 4 ordinal scale (P < .00001). Comparison of results across treatment and placebo arms was carried out to validate the initial findings. Logistic regression modelling further confirmed the results conditional on the presence of a number of potentially confounding covariates. Women were also 11% more likely than men to experience leukopenia of common toxicity criteria grade ≥ 1, (70% v 59%, respectively; P < .00001) and grade 3+ (18% v 11%, respectively; P = .004). CONCLUSION: More women than men reported 5-FU–induced stomatitis. The precise mechanism resulting in different degrees of stomatitis across sex is not evident.
HER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer
Stark, Azadeh , Hulka, Barbara S., Joens, Scott, Novotny, Debra B., Thor, Ann D. , Wold, Lester E., Melton, L. Joseph , Liu, Edison T. , Conway, Kathleen , Schell, Michael J.

Journal of Clinical Oncology | February 24, 2017 | Volume: 18 | Issue: 2 | Pages: 267-267

10.1200/jco.2000.18.2.267 | PMID 10637239 Get It

PURPOSE: The purpose of this study was to determine whether the presence of HER-2/neu gene amplification and/or overexpression in benign breast disease was associated with an increased risk of subsequent breast cancer. PATIENTS AND METHODS: We conducted a nested case-control study of a cohort of women who were diagnosed with benign breast disease at the Mayo Clinic and who were subsequently observed for the development of breast cancer. Patients who developed breast cancer formed the case group, and a matched sample from the remaining cohort served as controls. Benign tissue samples from 137 cases and 156 controls and malignant tissues from 99 cases provided DNA or tissue for evaluation of HER-2/neu amplification and protein overexpression. RESULTS: Among the controls, seven benign tissues (4.5%) demonstrated low-level HER-2/neu amplification, whereas 13 benign (9.5%) and 18 malignant (18%) tissue specimens from cases exhibited amplification. HER-2/neu amplification in benign breast biopsies was associated with an increased risk of breast cancer (odds ratio [OR] = 2.2; 95% confidence interval [CI], 0.9 to 5.8); this association approached statistical significance. The risks for breast cancer associated with benign breast histopathologic diagnoses were OR = 1.1 (95% CI, 0.6 to 1.9) for lesions exhibiting proliferation without atypia and OR = 1.5 (95% CI, 0.4 to 5.6) for the diagnosis of atypical ductal hyperplasia. For women having both HER-2/neu amplification and a proliferative histopathologic diagnosis (either typical or atypical), the risk of breast cancer was more than seven-fold (OR = 7.2; 95% CI, 0.9 to 60.8). Overexpression of the HER-2/neu protein product, defined as membrane staining in 10% or more of epithelial cells, was found in 30% of the breast tumors but was not detected in any of the benign breast tissues. Case patients who had HER-2/neu gene amplification in their malignant tumor were more likely to have had HER-2/neu amplification in their prior benign biopsy (P = .06, Fisher’s exact test). CONCLUSION: Women with benign breast biopsies demonstrating both HER-2/neu amplification and a proliferative histopathologic diagnosis may be at substantially increased risk for subsequent breast cancer.
p27kip1 Protein Expression Correlates With Survival in Myxoid and Round-Cell Liposarcoma
Oliveira, André M. , Okuno, Scott H. , Lloyd, Ricardo V., Nascimento, Antonio G.

Journal of Clinical Oncology | February 24, 2017 | Volume: 18 | Issue: 15 | Pages: 2888-2893

10.1200/jco.2000.18.15.2888 | PMID 10920137 Get It

PURPOSE: The p27kip1 protein (p27) is a cyclin-dependent kinase inhibitor that has been shown to be an independent prognostic factor in a variety of human neoplasms. Low expression of p27 tends to occur in more aggressive neoplasms. The role of p27 as an independent prognostic factor in the spectrum of myxoid and round-cell liposarcomas has not been examined. MATERIALS AND METHODS: Forty-seven cases of myxoid and round-cell liposarcomas were examined. Clinicopathologic features and immunohistochemical expression of p27 and Ki-67 antigen were studied in all cases. Survival analysis was performed using the log-rank test and the Cox multivariate regression model. RESULTS: The male:female ratio was 1.4:1, and the mean age at diagnosis was 45 years. The tumors were located in the lower extremities (94%) and retroperitoneum (6%). The median tumor size was 13.5 cm. The median follow-up was 6.3 years, and the overall 5- and 10-year survival rates were 76% and 67%, respectively. Low expression of p27 was identified in 34 cases (72%) and correlated with decreased metastasis-free (P = .026) and overall survival (P = .008). In a multivariate analysis, only round-cell differentiation and low expression of p27 independently predicted decreased metastasis-free and overall survival. CONCLUSION: p27 expression predicts the clinical behavior of myxoid and round-cell liposarcomas, even in neoplasms with few or no round-cell differentiation.
Preoperative Prediction of Surgical Margin Status in Patients With Prostate Cancer Treated by Radical Prostatectomy
Cheng, Liang , Bergstralh, Erik J., Myers, Robert P., Zincke, Horst, Bostwick, David G., Slezak, Jeff M. , Cheng, Liang

Journal of Clinical Oncology | February 24, 2017 | Volume: 18 | Issue: 15 | Pages: 2862-2868

10.1200/jco.2000.18.15.2862 | PMID 10920134 Get It

PURPOSE: We sought to determine the preoperative factors associated with surgical margin status in patients who underwent radical prostatectomy for prostate cancer. PATIENTS AND METHODS: The study group consisted of 339 patients who were treated by radical retropubic prostatectomy and bilateral pelvic lymphadenectomy at the Mayo Clinic. None received preoperative adjuvant therapy. The mean age at the time of surgery was 66 years (range, 45 to 79 years). All specimens were totally embedded and whole-mounted. Positive surgical margin was defined as the presence of cancer cells at the inked margins. Numerous pathologic characteristics in needle biopsies and preoperative clinical findings were analyzed. RESULTS: The overall margin positivity rate was 24%. In univariate analysis, preoperative serum prostate-specific antigen (PSA) level, Gleason score, perineural invasion, percentage of cancer in the biopsy specimens, and number and percentage of biopsy cores involved by cancer were all associated with positive surgical margins. In multivariate analysis, preoperative serum PSA level (odds ratio for a doubling of PSA levels, 1.9; 95% confidence interval, 1.5 to 2.4; P < .001) and percentage of cancer in the biopsy specimens (odds ratio for a 10% increase, 1.3; 95% confidence interval, 1.2 to 1.4; P < .001) were predictive of margin status in radical prostatectomy. With use of preoperative serum PSA level and percentage of cancer in the biopsy as predictors of surgical margins, the overall accuracy as measured by the area under the receiver operating characteristic curve was 0.74. CONCLUSION: Preoperative serum PSA level and percentage of cancer in the biopsy specimens were independently associated with surgical margin status in patients who underwent radical prostatectomy for prostate cancer. The combination of these two factors provides a high level of predictive accuracy for margin status.
Why Me?
Steensma, David P.

Journal of Clinical Oncology | February 24, 2017 | Volume: 20 | Issue: 3 | Pages: 873-875

10.1200/jco.2002.20.3.873 | PMID 11821476 Get It

A Revisitation of “Doc, How Much Time Do I Have?”
Schapira, Lidia , Eisenberg, Peter D., Mumber, Matthew P., Loprinzi, Charles L. , Macdonald, Neil

Journal of Clinical Oncology | February 24, 2017 | Volume: 18 | Issue: 13 | Pages: 2640-2643

10.1200/jco.2000.18.13.2640 | PMID 10893300 Get It

Doc, Shouldn’t We Be Getting Some Tests?
Loprinzi, Charles L. , Hayes, Daniel F. , Smith, Tom, Smith, Thomas J. , Smith, Tom, Smith, Thomas J

Journal of Clinical Oncology | February 24, 2017 | Volume: 18 | Issue: 11 | Pages: 2345-2348

10.1200/jco.2000.18.11.2345 | PMID 10829057 Get It

Screening for Lung Cancer: No Longer a Taboo Subject
Jett, James R.

Journal of Clinical Oncology | February 24, 2017 | Volume: 20 | Issue: 8 | Pages: 1959-1961

10.1200/jco.2002.20.8.1959 | PMID 11956250 Get It

Some Unusual Complications of Malignancies
Fanale, Michelle A. , Zeldenrust, Steven R., Moynihan, Timothy J.

Journal of Clinical Oncology | February 24, 2017 | Volume: 20 | Issue: 19 | Pages: 4111-4114

10.1200/jco.2002.20.19.4111 | PMID 12351608 Get It

Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes
Loprinzi, Charles L. , Sloan, Jeff A. , Perez, Edith A. , Quella, Susan K., Stella, Phillip J., Mailliard, James A., Halyard, Michele Y. , Pruthi, Sandhya , Novotny, Paul J. , Rummans, Teresa A.

Journal of Clinical Oncology | February 24, 2017 | Volume: 20 | Issue: 6 | Pages: 1578-1583

10.1200/jco.2002.20.6.1578 | PMID 11896107 Get It

PURPOSE: Hot flashes can be a prominent problem in women with a history of breast cancer. Given concerns regarding the use of hormonal therapies in such patients, other nonhormonal means for treating hot flashes are required. Based on anecdotal information regarding the efficacy of fluoxetine and other newer antidepressants for treating hot flashes, the present trial was developed. PATIENTS AND METHODS: This trial used a double-blinded, randomized, two-period (4 weeks per period), cross-over methodology to study the efficacy of fluoxetine (20 mg/d) for treating hot flashes in women with a history of breast cancer or a concern regarding the use of estrogen (because of breast cancer risk). Eligible patients had to have reported that they averaged at least 14 hot flashes per week; they could have received tamoxifen or raloxifene as long as they were on a stable dose. The major outcome measure was a bivariate construct representing hot flash frequency and hot flash score, analyzed by a classic sums and differences cross-over analysis. RESULTS: Eighty-one randomized women began protocol therapy. By the end of the first treatment period, hot flash scores (frequency × average severity) decreased 50% in the fluoxetine arm versus 36% in the placebo arm. Cross-over analysis demonstrated a significantly greater marked hot flash score improvement with fluoxetine than placebo (P = .02). The results were not adjusted for potential confounding influences, including age and tamoxifen use. The fluoxetine was well tolerated. CONCLUSION: This dose of fluoxetine resulted in a modest improvement in hot flashes.